A new report from congressional researchers is shedding light on what the Trump administration’s move to reclassify cannabis could mean for the industry, while also outlining the limits of the policy shift under federal law. As the ramifications of the recent decision to reclassify some marijuana products continue to become clearer, marijuana companies like Tilray Brands Inc. (NASDAQ: TLRY) will be able to ascertain how the changes may affect their operations and the broader market.
The report, released by the Congressional Research Service, examines the potential impact of rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. This move, proposed by the Trump administration, could reduce some federal restrictions on cannabis research and business operations. However, the report emphasizes that rescheduling would not legalize cannabis federally or resolve conflicts between state and federal laws. Key implications include possible tax benefits for cannabis businesses under Section 280E of the Internal Revenue Code, which currently prohibits deductions for businesses trafficking in Schedule I or II substances. A shift to Schedule III would allow these companies to deduct ordinary business expenses, potentially improving profitability for firms like Tilray.
Despite these benefits, the report highlights significant limitations. Cannabis would remain a controlled substance, meaning interstate commerce would still be prohibited without federal approval. Additionally, banking access for cannabis businesses would continue to be restricted under federal law, as financial institutions risk penalties for handling funds from Schedule III substances. The report also notes that rescheduling could facilitate research by easing restrictions on studying cannabis, but it would not automatically expand legal access for medical or recreational use. Industry observers expect that the move could encourage investment and consolidation among companies like Tilray, which has been expanding through acquisitions in the U.S. and Canada.
The news is important for investors and stakeholders in the cannabis industry as it provides a clearer regulatory roadmap. For Tilray Brands, the rescheduling could lower tax burdens and open doors for further growth. However, the report serves as a reminder that federal legalization remains a distant goal, and companies must continue to operate within a complex legal framework. The full report is available through the Congressional Research Service, and more updates can be found at CannabisNewsWire.
